(MedPage Today) — SAN FRANCISCO — The response rate in metastatic gastroesophageal cancer improved by a relative 50% when patients received experimental activated T cells in addition to standard therapy, according to a small phase II study…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.













